Regular Article
Inhibition of Angiotensin-converting Enzyme Increases the Nitric Oxide Levels in Canine Ischemic Myocardium

https://doi.org/10.1006/jmcc.1998.0806Get rights and content

Abstract

Since angiotensin-converting enzyme (ACE) produces angiotensin II in the heart, ACE inhibitors may prevent coronary vasoconstriction and increase coronary blood flow. On the other hand, since ACE inhibitors also inhibit kininase II which results in reduced degradation of bradykinin, ACE inhibitors may increase cardiac nitric oxide (NO) levels via stimulation of bradykinin receptors. This study was undertaken to test whether ACE inhibitors increase the cardiac NO levels and coronary blood flow in the ischemic myocardium. In 34 open-chest dogs, the left anterior descending coronary artery was perfused through an extracorporeal bypass tube from the left carotid artery. When either imidaprilat or cilazaprilat of 3μg/kg/min was infused into the bypass tube for 10 min after reduction of coronary blood flow due to partial occlusion of the bypass tube, coronary blood flow increased from 31±1 to either 45±5 or 43±4 ml/100 g/min despite no changes in coronary perfusion pressure (43±2 mmHg). During an infusion of either imidaprilat or cilazaprilat, bradykinin and the end-products of NO (nitrate+nitrite) concentrations of coronary venous blood were markedly increased, which were attenuated by either HOE-140 (an inhibitor of bradykinin receptors) or by Nω-nitro-L-arginine methyl ester (an inhibitor of NO synthase). We also observed increases in cardiac bradykinin and NO levels due to either imidaprilat or cilazaprilat in the low constant coronary blood flow condition. It is concluded that ACE inhibitors can increase cardiac NO levels via the accumulation of bradykinin in the ischemic myocardium.

References (0)

Cited by (21)

  • No altered blood pressure and serum markers of oxidative stress after a long time dietary fish oil in the genetically 9 month-old type-2 diabetes Zucker rat

    2010, Prostaglandins Leukotrienes and Essential Fatty Acids
    Citation Excerpt :

    Our results revealed an inverse relationship between ACE activity and NO levels. This should be related to the fact that inhibition of ACE is known to trigger an increase in NO levels, as previously reported in canine ischemic myocardium [42] and in bovine aortic endothelial cells [43]. Moreover, these results are consistent with the study of Takemoto et al., which showed long-term inhibition of NO production (by L-NAME) causes high ACE activity in heart and aorta [44].

  • Participation of kallikrein-kinin system in different pathologies

    2008, International Immunopharmacology
    Citation Excerpt :

    Several studies have shown that kinins exert cardioprotective effects on myocardial infarct and heart failure, such as reduction of both left ventricular hypertrophy and progression of heart failure [19–22]. The protective effects of BK are mainly mediated by B2 receptor due to NO production by endothelial cells [23,24], induction of antiproliferative effects on fibroblasts [25,26] and antihypertrophic effects on cardiomyocytes [27,28]. Yao and coworkers [29] showed that kallikrein infusion in rats for 7 days after myocardial infarct induction improved cardiac function, normalized left ventricular wall thickness, and reduced macrophage infiltration in the infarcted heart.

  • Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells

    2007, Journal of Molecular and Cellular Cardiology
    Citation Excerpt :

    The cardioprotective effects are mainly mediated by a G-protein coupled receptor, the bradykinin type-2 receptor (BK-2R). Activation of BK-2Rs triggers the production and release of NO, EDHF and prostaglandins by the endothelial cells in the myocardium [4–7]. In addition, BK and Lys-BK mediate antiproliferative [8,9] and antihypertrophic [10,11] effects on fibroblasts and myocytes, respectively.

View all citing articles on Scopus
f1

Please address correspondence to: Masafumi Kitakaze, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan.

View full text